FOLFOX6方案对进展期胃癌新辅助化疗的临床疗效

Effects of FOLFOX6 neoadjuvant chemotherapy protocol on advanced gastric cancer

目的探讨FOLFOX6方案对进展期胃癌新辅助化疗的临床疗效。方法将2012—2013年我院胃肠外科收治的86例胃癌患者分为两组，对照组46例采用外科手术加辅助化疗，观察组40例采用FOLFOX6为主的新辅助化疗一手术一术后辅助化疗，观察新辅助化疗对进展期胃癌的作用和毒性反应。结果FOLFOX6新辅助化疗组，临床总有效率为50％（20／40）。毒副作用轻，大多数毒性都是I级或者Ⅱ级，无患者因为化疗的不良反应而退出试验；无死亡病例。观察组根治率为82．5％，与对照组的60．8％相比明显增高，P〈0．05；术后并发症发生率并无增加。结论FOL-FOX6新辅助化疗方案能提高进展期胃癌R0切除率，毒性反应较低，不增加手术并发症，是安全有效的方案。

OBJECTIVE To explore the FOLFOX6 scheme the clinical curative effect of new adjuvant chemotherapy for advanced gastric cancer. METHODS 86 patients with gastric cancer from 2012 to 2013 I was admitted to hospital gastrointestinal surgery divided into two groups, a control group of 46 patients using surgery plus adjuvant chemotherapy was observed 40 cases of neoadjuvant chemotherapy using FOLFOX6 based-surgery-surgery adjuvant chemotherapy, ob- served effects and toxicity of neoadjuvant chemotherapy in advanced gastric cancer. RESULTS FOLFOX6 neoadjuvant chemotherapy group, total effective rate was 50%（20/40）. Mild side effects, most toxic are Class Ⅰ or Class Ⅱ , no pa tients because of adverse effects of chemotherapy and withdraw from the trial＇ no deaths. Radical observation group was 82.5%, compared with 60.8% in the control group was significantly higher, P〈0.05;no increase in the incidence of postoperative complications. CONCLUSION FOLFOX6 neoadjuvant chemotherapy can improve advanced gastric R0 re- section rate, low toxicity, no increased surgical complications, is a safe and effective program.